NCT04039516View on ClinicalTrials.gov

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Carcinoid Heart DiseaseCarcinoid SyndromeCarcinoid Tumor
Interventions
DRUG

Lutathera

A total of 4 infusions of Lutathera to be administered every 8 weeks.

Sponsors
All Listed Sponsors
collaborator

Advanced Accelerator Applications

INDUSTRY

lead

King's College Hospital NHS Trust

OTHER